Avantor, Inc. (NYSE:AVTR) Short Interest Up 24.1% in June

Avantor, Inc. (NYSE:AVTR) saw a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 17,670,000 shares, a growth of 24.1% from the May 31st total of 14,240,000 shares. Based on an average daily volume of 5,410,000 shares, the short-interest ratio is presently 3.3 days.

Institutional Trading of Avantor

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AVTR. American Trust grew its position in shares of Avantor by 45.1% during the 1st quarter. American Trust now owns 13,261 shares of the company’s stock worth $339,000 after buying an additional 4,121 shares during the period. Westwood Holdings Group Inc. grew its position in shares of Avantor by 10.5% during the 1st quarter. Westwood Holdings Group Inc. now owns 723,084 shares of the company’s stock worth $18,489,000 after buying an additional 68,541 shares during the period. DekaBank Deutsche Girozentrale grew its position in shares of Avantor by 146.7% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 400,736 shares of the company’s stock worth $10,205,000 after buying an additional 238,285 shares during the period. Boston Partners grew its position in shares of Avantor by 2.2% during the 1st quarter. Boston Partners now owns 28,561,802 shares of the company’s stock worth $729,298,000 after buying an additional 624,369 shares during the period. Finally, Cetera Advisors LLC acquired a new stake in shares of Avantor during the 1st quarter worth approximately $249,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on AVTR. Deutsche Bank Aktiengesellschaft upped their price target on shares of Avantor from $23.00 to $25.00 and gave the stock a “hold” rating in a research report on Thursday, April 18th. Evercore ISI decreased their price objective on shares of Avantor from $28.00 to $27.00 and set an “outperform” rating on the stock in a report on Tuesday. Barclays decreased their price objective on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday. Finally, Robert W. Baird decreased their price objective on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a report on Monday, April 29th. Four research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, Avantor currently has an average rating of “Moderate Buy” and a consensus price target of $26.29.

Avantor Trading Down 0.9 %

NYSE AVTR traded down $0.19 during trading hours on Tuesday, reaching $20.58. The company’s stock had a trading volume of 5,348,864 shares, compared to its average volume of 5,824,606. The firm has a fifty day simple moving average of $23.66 and a 200-day simple moving average of $23.81. The stock has a market cap of $13.98 billion, a P/E ratio of 52.77, a P/E/G ratio of 2.15 and a beta of 1.32. Avantor has a 52 week low of $16.63 and a 52 week high of $26.16. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.61 and a quick ratio of 1.05.

Avantor (NYSE:AVTR) last issued its quarterly earnings data on Friday, April 26th. The company reported $0.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.02. The business had revenue of $1.68 billion during the quarter, compared to analyst estimates of $1.68 billion. Avantor had a net margin of 3.79% and a return on equity of 13.01%. The firm’s quarterly revenue was down 5.6% on a year-over-year basis. During the same quarter last year, the business earned $0.29 EPS. Equities analysts forecast that Avantor will post 1.01 earnings per share for the current fiscal year.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.